- Home
- MCRB vs RILY Comparison
MCRB vs RILY Comparison
Compare MCRB & RILY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- RILY
- Stock Information
- Founded
- MCRB 2010
- RILY 1973
- Country
- MCRB United States
- RILY United States
- Employees
- MCRB N/A
- RILY N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- RILY Investment Managers
- Sector
- MCRB Health Care
- RILY Finance
- Exchange
- MCRB Nasdaq
- RILY Nasdaq
- Market Cap
- MCRB 141.9M
- RILY 142.1M
- IPO Year
- MCRB 2015
- RILY 2007
- Fundamental
- Price
- MCRB $0.37
- RILY $3.16
- Analyst Decision
- MCRB Hold
- RILY
- Analyst Count
- MCRB 5
- RILY 0
- Target Price
- MCRB $4.00
- RILY N/A
- AVG Volume (30 Days)
- MCRB 1.3M
- RILY 858.4K
- Earning Date
- MCRB 05-07-2025
- RILY 04-29-2025
- Dividend Yield
- MCRB N/A
- RILY 17.86%
- EPS Growth
- MCRB N/A
- RILY N/A
- EPS
- MCRB 0.00
- RILY N/A
- Revenue
- MCRB N/A
- RILY $854,383,000.00
- Revenue This Year
- MCRB N/A
- RILY N/A
- Revenue Next Year
- MCRB N/A
- RILY N/A
- P/E Ratio
- MCRB $474.36
- RILY N/A
- Revenue Growth
- MCRB N/A
- RILY N/A
- 52 Week Low
- MCRB $0.46
- RILY $2.67
- 52 Week High
- MCRB $1.53
- RILY $40.09
- Technical
- Relative Strength Index (RSI)
- MCRB 28.34
- RILY 39.62
- Support Level
- MCRB $0.36
- RILY $2.74
- Resistance Level
- MCRB $0.67
- RILY $3.44
- Average True Range (ATR)
- MCRB 0.07
- RILY 0.34
- MACD
- MCRB -0.02
- RILY -0.02
- Stochastic Oscillator
- MCRB 2.71
- RILY 37.69
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About RILY B. Riley Financial Inc.
B. Riley Financial Inc is a diversified financial services company. The company through its subsidiaries offers investment banking and financial services to corporate, institutional, and high-net-worth clients and also asset disposition, valuation and appraisal, and capital advisory services to retail, wholesale, institutional, lenders, capital providers, private equity investors, and professional services firms in United States, Canada, and Europe. It also provides internet access and subscription services. The reportable operating segments of the company include Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications segment, and Consumer products segment.